They did ask for full MDR2. That is what the FDA should have done, but didn't approve. I'm not sure if BP could have done better (maybe grease the palm or something) On a similar note did you see the old FDA commissioner joining the BOD for Pfizer ? They didn't drop Maraviroc until they up the enrollment to 50, which made me think that was an issue.

https://www.cnbc.com/2019/06/27/former-fda-co...board.html